
## Harpreet S Bhatia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4293829/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Systolic dysfunction in patients with methamphetamine use and heart failure with preserved ejection fraction. International Journal of Cardiology, 2022, 348, 90-94.	0.8	6
2	Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. Atherosclerosis, 2022, 349, 144-150.	0.4	9
3	State-of-the-Art Review: Evidence on Red Meat Consumption and Hypertension Outcomes. American Journal of Hypertension, 2022, 35, 679-687.	1.0	4
4	Coronary artery calcium incidence and changes using direct plaque measurements: The MASALA study. Atherosclerosis, 2022, 353, 41-46.	0.4	5
5	Density of Calcified Coronary Artery Plaque and Risk of Incident Atrial Fibrillation (from the) Tj ETQq1 1 0.784314	4 rgBT /Ov	erlock 10 Tf
6	Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation. Heart, 2021, 107, 741-747.	1.2	9
7	Causative Mechanism of Constrictive Pericarditis Diagnosed by Fluoroscopy. JAMA Cardiology, 2021, 6, e210616.	3.0	1
8	Subclinical left ventricular dysfunction in COVID-19. IJC Heart and Vasculature, 2021, 34, 100770.	0.6	19
9	Methamphetamineâ€Associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities. Journal of the American Heart Association, 2021, 10, e018370.	1.6	19
10	Association of coronary artery calcification and thoracic aortic calcification with incident peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). European Heart Journal Open, 2021, 1, oeab042.	0.9	0
11	Response to "Direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease― PACE - Pacing and Clinical Electrophysiology, 2020, 43, 267-267.	0.5	Ο
12	The Impact of Substance Abuse on Heart Failure Hospitalizations. American Journal of Medicine, 2020, 133, 207-213.e1.	0.6	44
13	Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1463-1470.	0.5	5
14	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. Clinical Cardiology, 2018, 41, 1395-1402.	0.7	23